Therapies and compositions for reducing collagen synthesis in mammalian cells and tissues wherein the targets are scleraxis, sclerax-is-binding sites, receptor-regulated Smads, and/or binding sites for receptor-regulated Smads whereby synergistic interactions between scleraxis proteins and receptor-regulated Smads are reduced, inhibited, interfered with, stopped, and/or prevented thereby reducing, inhibiting and/or interfering with the activation of collagen 1&alpha；2 promoter thereby inhibiting collagen production in mammalian cells and tissues. Alternatively, the therapies and compositions may reduce, inhibit, interfere with, stop, and/or prevent binding of the collagen 1&alpha；2 promoter to DNA thereby inhibiting expression of the collagen 1&alpha；2 gene in mammalian cells and tissues.
